Company Analysis
Sign in

Verastem, Inc. (VSTM)

Nasdaq: VSTM · Pharmaceutical Preparations · Needham, MA · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.3
◀ Past 5.6● Present 3.9▶ Future 6.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

13 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Verastem, Inc.’s names, not what it holds today.

Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
30
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'12'13'14'15'16'18'19'20'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Verastem, Inc. its own name
named as the applicant on its applications, in US
0 granted
25 published
Verastem, Inc. its own name
US, as the owner printed on each patent
13 granted
5 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,509,450Solid forms of a dual RAF/MEK inhibitorOrganic fine chemistryVerastem, Inc.
Jan 16, 202411,873,296Solid forms of a dual RAF/MEK inhibitorPharmaceuticalsVerastem, Inc.
Jan 31, 202311,564,927Therapeutic compositions, combinations, and methods of usePharmaceuticalsVerastem, Inc.
Jan 14, 202010,532,056Therapeutic compositions, combinations, and methods of usePharmaceuticalsVerastem, Inc.
Sep 10, 201910,406,158Methods and compositions for treating abnormal cell growthPharmaceuticalsVerastem, Inc.
May 8, 20189,962,385Methods and compositions for treating abnormal cell growthPharmaceuticalsVerastem, Inc.
Nov 29, 20169,505,719Synthesis and use of kinase inhibitorsPharmaceuticalsVerastem, Inc.
Jun 28, 20169,375,402Oral formulations of kinase inhibitorsPharmaceuticalsVerastem, Inc.
Sep 22, 20159,138,437Pyrimidine substituted purine compounds as kinase (S) inhibitorsPharmaceuticalsVerastem, Inc.
Jun 17, 20148,754,080Pyrimidine substituted purine compounds as kinase (S) inhibitorsPharmaceuticalsVerastem, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367201COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Mar 27, 20252025/0099467COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Feb 27, 20252025/0064804COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Feb 13, 20252025/0049792COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Jan 9, 20252025/0009746COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Nov 21, 20242024/0382485METHODS OF TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Oct 17, 20242024/0343714SOLID FORMS OF A DUAL RAF/MEK INHIBITORPharmaceuticalsVerastem, Inc. · patent 12,509,450 granted from it
Apr 11, 20242024/0115571COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTHPharmaceuticalsVerastem, Inc.
Jan 4, 20242024/0000790THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USEPharmaceuticalsVerastem, Inc.
Dec 7, 20232023/0391759SOLID FORMS OF A DUAL RAF/MEK INHIBITORPharmaceuticalsVerastem, Inc. · patent 11,873,296 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 9.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VSTM · research, not advice